Cardiac electrophysiologist James D. Allred, M.D., and vascular surgeon Wells Brabham, M.D., perform Novel Ultrasound-Guided Implant Approach at Moses H. Cone Memorial Hospital, Greensboro, North Carolina.
FREMONT, CA: CVRx®, the developer of the world's first FDA-approved neuromodulation device to treat heart failure (HF) symptoms, declares the successful completion of the company's first clinical procedure using its novel lead implantation approach. The novel ultrasound-guided technique is the most recent development in CVRxs Barostim, Baroreflex Activation Therapy (BAT) to treat HF symptoms. The new system simplifies the implant procedure by guiding a slight stimulation lead near the targeted carotid baroreceptors using minimally invasive techniques and ultrasound imaging.
Commenting on the technology, cardiac electrophysiologist Dr. James D. Allred, M.D., “This new approach to treatment represents a potentially game-changing advancement in the way we manage patients with HF symptoms. We are excited to participate in this study evaluating the ultrasound-guided approach as a new implant technique to deliver this therapy.”
“We are pleased to have participated in this first-in-human procedure at our center,” says Dr. Brabham. “We are excited by this new approach, and we are happy to contribute towards the investigation of a new way to deliver this important therapy to patients.”
"Congratulations to Drs. Allred and Brabham and Moses Cone Hospital on successfully completing this first clinical procedure in the study of this new implant technique," says Nadim Yared, President, and CEO of CVRx. "We value our collaboration with them and commend their ongoing efforts to advance neuromodulation to treat HF symptoms.”